At a glance
ClinicalIndex Comparison RecordN/ACompleted· 22 enrolled
Drug / intervention
Lapatinib Ditosylate +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Neoadjuvant Trial of Lapatinib for the Treatment of Women With DCIS Breast Cancer
In Brief
A clinical study evaluating Laboratory Biomarker Analysis, Lapatinib Ditosylate, and 1 other intervention for Ductal Breast Carcinoma In Situ and HER2/Neu Positive. Completed, enrolled 22 participants across 2 sites.
Detailed Summary
This randomized phase I/II trial studies the side effects and best dose of lapatinib ditosylate and to see how well it works in treating patients with ductal breast carcinoma in situ. Lapatinib ditosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDuctal Breast Carcinoma In Situ, HER2/Neu Positive
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 2007
Enrollment StartAug 2009
Primary CompletionAug 2014
TodayJul 2026
First PostedNov 7, 2007
Enrollment StartAug 19, 2009
Primary CompletionAug 28, 2014
TodayJul 2, 2026
Enrollment to primary: 5.0 yearsPosted 18.7 years ago
Interventions
Laboratory Biomarker Analysisother
Correlative studies
Lapatinib Ditosylatedrug
Given PO
Placeboother
Given PO